Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.21.2
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 01, 2021
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation of Revenue [Line Items]          
Total revenue   $ 1,350 $ 1,111 $ 5,179 $ 5,202
Product Revenue          
Disaggregation of Revenue [Line Items]          
Total revenue   $ 1,350 1,111 4,554 5,202
Millipred | Teva          
Disaggregation of Revenue [Line Items]          
Percent of net profit for installment payments   50.00%      
Installment payment $ 500        
Royalty expense   $ 700   700  
License revenue          
Disaggregation of Revenue [Line Items]          
Total revenue   $ 0 $ 0 $ 625 $ 0
Sales Revenue | Customer Concentration Risk | Major Customer Number One          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   52.00%   62.00%  
Sales Revenue | Customer Concentration Risk | Major Customer Number Two          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   24.00%   20.00%  
Sales Revenue | Customer Concentration Risk | Major Customer Number Three          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   24.00%   17.00%